Figure 2From: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialSchema of exosome purification processes. Exosomes were purified from monocyte derived-DC (MD-DC) culture supernatants according to a good manufacturing process already described [26]. In the second part of the trial, indirect loading of MHC class II peptides (MAGE3247–258.DP04, KKLLTQHFVQENYLEY) was performed on DC cultures followed, after exosome purification by a direct loading of MHC class I (MAGE3168–176.A1/B35; EVDPIGHLY) peptides at 10 or 100 μg/ml at pH 4.2 [22]. Quality control parameters included dosing of exosomal MHC class II molecules, flow cytometry analyses and functional assays using superantigens as described in material and methods.Back to article page